AKT1 and esophageal squamous cell carcinoma: Among the 30 candidate compounds selected, three compounds—D332-0030, V020-9974 and V025-1375—inhibited cell survival and AKT signaling activation in ESCC cells (Fig. 6c; Supplementary Fig. S5a).